The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index; 46 of the 120 sources its claims cite were checked for support.
An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact
Open accessAbstract
Paracetamol remains the recommended first-line option for mild-to-moderate acute pain in general population and particularly in vulnerable populations. Despite its wide use, debate exists regarding the analgesic mechanism of action (MoA) of paracetamol. A growing body of evidence challenged the notion that paracetamol exerts its analgesic effect through cyclooxygenase (COX)-dependent inhibitory effect. It is now more evident that paracetamol analgesia has multiple pathways and is mediated by the formation of the bioactive AM404 metabolite in the central nervous system (CNS). AM404 is a potent activator of TRPV 1 , a major contributor to neuronal response to pain in the brain and dorsal horn. In the periaqueductal grey, the bioactive metabolite AM404 activated the TRPV 1 channel‐mGlu5 receptor‐PLC‐DAGL‐CB1 receptor signaling cascade. The present article provides a comprehensive literature review of the centrally located, COX-independent, analgesic MoA of paracetamol and relates how the current experimental evidence can be translated into clinical practice. The evidence discussed in this review established paracetamol as a central, COX-independent, antinociceptive medication that has a distinct MoA from non-steroidal anti-inflammatory drugs (NSAIDs) and a more tolerable safety profile. With the establishment of the central MoA of paracetamol, we believe that paracetamol remains the preferred first-line option for mild-to-moderate acute pain for healthy adults, children, and patients with health concerns. However, safety concerns remain with the high dose of paracetamol due to the NAPQI-mediated liver necrosis. Centrally acting paracetamol/ p -aminophenol derivatives could potentiate the analgesic effect of paracetamol without increasing the risk of hepatoxicity. Moreover, the specific central MoA of paracetamol allows its combination with other analgesics, including NSAIDs, with a different MoA. Future experiments to better explain the central actions of paracetamol could pave the way for discovering new central analgesics with a better benefit-to-risk ratio. Keywords: paracetamol, acetaminophen, AM404, analgesia, molecular targets
Overview
CoChat Summary
TL;DR
This review argues that paracetamol analgesia is centrally mediated by its AM404 metabolite and is largely COX-independent, involving TRPV1, CB1, Cav3.2, and serotonergic pathways. It concludes that paracetamol remains a first-line option for mild-to-moderate acute pain and that centrally acting paracetamol analogs may improve analgesia without NAPQI-mediated hepatotoxicity.
Key findings
- Paracetamol is converted centrally to the bioactive metabolite AM404: after hepatic deacetylation to p-aminophenol, FAAH converts it to AM404 in the brain. The first human evidence detected AM404 in cerebrospinal fluid in 17 of 26 patients who received 1 g paracetamol.
- AM404 activates TRPV1 and, in the periaqueductal grey, the TRPV1 channel–mGlu5 receptor–PLC–DAGL–CB1 receptor signaling cascade; Cav3.2 T-type calcium channels act mainly supraspinally and downstream of TRPV1, and serotonergic pathways also contribute.
- The analgesic mechanism is described as COX-independent: paracetamol’s antinociceptive profile differs from ibuprofen, COX-3 is unlikely to be clinically relevant in humans, and COX inhibition is more closely related to hypothermic/antipyretic effects.
- Clinically, paracetamol is presented as first-line for mild-to-moderate acute pain in healthy adults, children, and patients with health concerns; the maximum recommended dose is 1 g every 4–6 hours up to 4 g/day, while hepatotoxicity from NAPQI remains a major safety issue.
Methods
- Narrative literature review: Medline via PubMed was searched from inception to May 2022 using the keywords (paracetamol[MeSH Terms]) OR (acetaminophen[MeSH Terms])) AND (AM404), complemented by manual screening of relevant references.
- Evidence was synthesized narratively from experimental animal studies, human cerebrospinal fluid and genetic studies, clinical trials, and a table of selected randomized trials of paracetamol plus opioids for acute postoperative pain.
- No systematic review, meta-analysis, or formal quantitative synthesis was reported.
Limitations
- The paper states that evidence for the morphine-sparing effect of paracetamol/opioid combinations is limited and further studies are needed; the exact nature of the spinal tropisetron-sensitive receptor involved remains to be elucidated; and how CB1 receptors are involved requires further study.
- The paper states that safety issues remain controversial or inconclusive, including hepatotoxicity, and that some combination safety signals—such as hemoglobin decreases with longer-term paracetamol/ibuprofen and upper GI events with NSAID plus acetaminophen—warrant further research.
- Evident from the text: as a narrative review, it does not report a systematic search beyond PubMed and the AM404 keyword strategy, nor a formal quality/risk-of-bias assessment or quantitative synthesis, so clinical recommendations rest on selected evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
34 Valid · 3 Not valid · 35 Not checked · 34 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2014, Kerckhove et al demonstrated that Cav3.2 knockout mice had impaired response to the analgesic effect of a systemic administration of paracetamol or intracerebroventricular injection of AM404.55”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404-Modulated Molecular Targets > Downstream Targets of TRPV1
What the sources say
- Partly supportedcites [55] Barbara, 2009, J Neurosci sourceExperimental — accuracy not yet measured
The section “NAGly and NAGABA-OH produce thermal analgesia via Cav3.2 inhibition” reports that these compounds produced analgesia in wild-type mice but not Cav3.2 knockout mice. The Behavioral studies methods describe hindpaw injections, not systemic paracetamol or intracerebroventricular AM404; our copy does not report responses to either drug by those routes. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Importantly, it has been shown that 1) centrally injected AM404 induced analgesia37,44,45”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404: The Active Metabolite of Paracetamol
What the sources say
- Supportedcites [37] Mallet, 2010, PLoS One source
The Results report that intracerebroventricular injection of AM404 reduced pain-related behavior in the mouse formalin test. The authors conclude in the Results that AM404 produces antinociception when injected into the brain, supporting the claim that centrally injected AM404 induces analgesia. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [44] Rastogi, 2008, J Clin Oncol source
- Supportedcites [45] Kerckhove, 2014, Pain source
The Results (Manuscript-KERCKHOVE, p. 9) report that intracerebroventricular injection of AM404 induced analgesia in Cav3.2 +/+ mice in the formalin and von Frey tests. The same passage notes that this effect was not observed in Cav3.2 -/- mice. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, paracetamol remains the mainstay analgesic option in patients with chronic kidney disease.92”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol, a COX-Independent, Centrally Acted as the First Choice for a Wide Range of Special Populations
What the sources say
- Supportedcites [92] Davison, 2020, Can J Kidney Heal Dis source
The Discussion states that acetaminophen (paracetamol) is the mainstay of treatment for mild to moderate pain in patients with CKD. This supports the citing sentence’s description of it as a mainstay analgesic option. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.94–96”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol, a COX-Independent, Centrally Acted as the First Choice for a Wide Range of Special Populations
What the sources say
- Supportedcites [94] White, 2018, J Cardiovasc Pharmacol Ther source
The Cardiovascular Events From Clinical Trials section says no randomized trial of OTC acetaminophen was adequate to assess cardiovascular risk. In Patients With Hypertension, the review reports that a short trial in patients with coronary artery disease observed no cardiovascular events. This supports the claim about a lack of robust event evidence in that patient group, not a conclusion that acetaminophen is risk-free. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [95] Dawson, 2013, J Hypertens source
- Not checked — no full text of the sourcecites [96] Fulton, 2015, Hypertension source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, several molecular actors targeted by the bioactive AM404, including the Cav3.2 calcium channel, the cannabinoid CB1 receptors and TRPV1 receptors, would participate in the MoA.10,20,21”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Introduction
What the sources say
- Partly supportedcites [10] Ohashi, 2020, Front Pharmacol sourceExperimental — accuracy not yet measured
The ‘Activating the Transient Receptor Potential Vanilloid 1 and Cannabinoid 1 Receptors’ section describes AM404 acting on TRPV1 and CB1 receptors in acetaminophen analgesia, although it reports no CB1-mediated effect in the spinal dorsal horn at the dose studied. Neither that section nor the analgesic-mechanisms table identifies Cav3.2 as an AM404 target or participant in the mechanism. (LLM, conf=0.87)
- Partly supportedcites [20] Muramatsu, 2016, Anesthesiol Pain Med sourceExperimental — accuracy not yet measured
The Background (page not provided) identifies AM404 as an activator of TRPV1 and a ligand at cannabinoid CB1 receptors. The Discussion (page not provided) says brain TRPV1 may be involved in acetaminophen’s antinociceptive action. Our copy does not mention Cav3.2, so it does not support that part of the claim. (LLM, conf=0.88)
- Partly supportedcites [21] Saliba, 2017, J Neuroinflammation sourceExperimental — accuracy not yet measured
The Background (page unavailable) identifies AM404 as a paracetamol metabolite that acts on TRPV1 and binds CB1, and suggests AM404 may contribute to paracetamol’s analgesic mechanism. Our copy does not identify Cav3.2 as an AM404 target or participant in that mechanism. The Results and Discussion (page unavailable) also find that AM404’s anti-inflammatory effect in microglia is independent of CB1 and TRPV1; that narrower finding does not rule out their participation in other effects. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 12 with their cited sources checked
Create a free account to see all 106 claims and to verify the 12 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 14
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404: The Active Metabolite of Paracetamol
“Importantly, it has been shown that 1) centrally injected AM404 induced analgesia37,44,45”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > References
“44. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008; 26(5): 778– 785.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol in Combination with Other Analgesics
“Experimental evidence showed that paracetamol had a synergistic effect on gabapentin.126”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > References
“126. Mititelu Tartau L, Popa EG, Lupusoru RV, Lupusoru CE, Stoleriu I, Ochiuz L. Synergic effects of pregabalin-acetaminophen combination in somatic and visceral nociceptive reactivity.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol in Combination with Other Analgesics
“However, a 13-week trial showed patients on paracetamol/ibuprofen combination had a higher risk of decreases in hemoglobin level (≥1 g/dl) than monotherapy, suggesting a potential risk of bleeding on long-term use of paracetamol/ibuprofen combination.122”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > Potential Clinical Consequences of the Centrally Located Analgesic Action of Paracetamol > Paracetamol in Combination with Other Analgesics
“| Daniels et al, 2011122 | Dental | Double-blind RCT | 678 | Ibuprofen/Paracetamol 400 mg/1000 mgIbuprofen/Paracetamol 200 mg/500 mgIbuprofen/Codeine 400 mg/25.6 mgCodeine/ Paracetamol 30 mg/1000 mgPlacebo | Single dose, postoperative |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > AM404-Modulated Molecular Targets > Downstream Targets of TRPV1
“In 2014, Kerckhove et al demonstrated that Cav3.2 knockout mice had impaired response to the analgesic effect of a systemic administration of paracetamol or intracerebroventricular injection of AM404.55”
§ An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact > References
“55. Barbara G, Alloui A, Nargeot J, et al. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci. 2009; 29(42): 13106– 13114.”
Citations
Cites
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989 · cited 1×
“COX-3 is an exon splice variant from COX-1 that was identified in the canine cerebral cortex and exhibited selective sensitivity to paracetamol.(34) However, further genomic and kinetic studies showed that a full-length, catalytically active form of COX-3 does not exist in humans(35,36) and that the COX-3 selective in…”
BackgroundRastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh-ishi, S., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003505200 · Cited by 964
Descending control of nociception: Specificity, recruitment and plasticity
Heinricher, M. M., Tavares, I., Leith, J. L., & Lumb, B. M. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.009 · Cited by 949 · cited 1×
“Serotonin appears to have both inhibitory and facilitative effects on pain.(58) The involvement of the serotonergic pathway in the analgesic effect of paracetamol was described even before the 2005 work by Högestätt et al.”
BackgroundAntman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804 · cited 1×
“According to an American Heart Association position statement, paracetamol should be preferred over NSAIDs in patients with coronary artery disease.(100) Aspirin and other NSAIDs significantly increase the risk of gastrointestinal ulcers and bleeding.”
BackgroundFLOWER, R. J., & VANE, J. R. (1972) · Nature · doi:10.1038/240410a0 · Cited by 779 · cited 2×
“Flower and Vane demonstrated that the COX inhibitory effect of paracetamol was more potent in the brain than in the spleen, suggesting another COX isoenzyme as a sensitive site for paracetamol action.(8) COX-3 is an exon splice variant from COX-1 that was identified in the canine cerebral cortex and exhibited selectiv…”
BackgroundParacetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674 · cited 1×
“Despite its wide use, debate exists regarding the analgesic mechanism of action (MoA) of paracetamol.(7) Historically, it was believed that the paracetamol-mediated analgesia stems solely from its cyclooxygenase (COX)dependent inhibitory effect on prostaglandin (PG) synthesis(8); however, it is now evident that the an…”
BackgroundGraham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Mechanism of Action of Paracetamol
Graham, G. G., & Scott, K. F. (2005) · American Journal of Therapeutics · doi:10.1097/00045391-200501000-00008 · Cited by 648 · cited 1×
“However, further genomic and kinetic studies showed that a full-length, catalytically active form of COX-3 does not exist in humans(35,36) and that the COX-3 selective interaction is unlikely to be clinically relevant.(31) However, the question remained whether the analgesic MoA of paracetamol is primarily mediated by…”
Background
Research works printed but not linked: 4
- Boutaud, 2002, Proc Natl Acad Sci U S A, 99, 7130, 10.1073/PNAS.102588199/ASSET/682AB754-3CF6-4EC9-B4FB-18483C903C21/ASSETS/GRAPHIC/PQ1025881008.JPEG · doi:10.1073/pnas.102588199/asset/682ab754-3cf6-4ec9-b4fb-18483c903c21/assets/graphic/pq1025881008.jpeg
- Jozwiak-Bebenista, 2014, Acta Pol Pharm Drug Res, 71, 11
- Evke, 2022, Genes, 13, 10.3390/GENES13030421/S1 · doi:10.3390/genes13030421/s1
- Schug, 2006, Clin Rheumatol, 25, 16, 10.1007/S10067-006-0202-9/FIGURES/5 · doi:10.1007/s10067-006-0202-9/figures/5
Cited by
Inflammation and cancer: friend or foe?
Smith, A. D. T., Córdoba-Hernandez, S., Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., & Rodríguez-García, J. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1385479 · Cited by 58
Hallmarks of primary headache: part 2– Tension-type headache
Pan, L. H., Ling, Y., Wang, S., Al‐Hassany, L., Chen, W., Chiang, C., Cho, S., Chu, M. K., Coppola, G., Pietra, A. D., et al. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-02098-w · Cited by 61
“…effects primarily through the peripheral inhibition of the cyclooxygenase (COX-1 and COX-2) pathway, whereas paracetamol analgesic effects are more complex and involve inhibition of COX-2 and other central pathways, such as the endocannabinoid and serotonergic pathways (reviewed in [295, 296]).”
Pain Management in Children Admitted to the Emergency Room: A Narrative Review
Cunico, D., Rossi, A., Verdesca, M., Principi, N., & Esposito, S. (2023) · Pharmaceuticals · doi:10.3390/ph16081178 · Cited by 29
“This is formed in the central nervous system (CNS) from the liver metabolite of PC, p-aminophenol, under the action of the fatty acid amide hydrolase (FAAH) enzyme [63].”
BackgroundMolecular Mechanisms of Chronic Pain and Therapeutic Interventions
Li, Z., Li, X., Liu, J., Sun, R., Ye, Y., Xiang, H., Luo, F., Li, S., & Luo, A. (2025) · MedComm · doi:10.1002/mco2.70325 · Cited by 36
“2 channel, thereby reinforcing the activity of descending serotonergic pathways [316] CPPP, OA, headache, migraine attacks [316–318] Tricyclic antidepressants (TCAs) Hindering the reuptake process of serotonin and noradrenaline [2, 319]; modulation of opioid, glutamatergic and endocannabinoid…”
Jasim, M. H. M., & Mustafa, Y. F. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401309 · Cited by 20
Metadata
- Authors
- Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A.
- Affiliations
- Inserm (FR)
- University of Geneva (CH)
- Corresponding author
- Eschalier, Alain
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2023-03
- Volume
- Volume 16
- Pages
- 1081-1094
- ISSN
- 1178-7090 (ISSN-L)
- PMC
- PMC10066900
- OpenAlex
- W4361217917
- Cited by
- 83
- References
- 137
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 17 · 2023: 11
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Pain Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- paracetamol, analgesic mechanism, TRPV1, periaqueductal gray, mGlu5 receptor, central analgesia, acute pain, NSAID combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact. https://app.cochat.ai/papers/10.2147/jpr.s393809
- The paper
- Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023). An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact. Journal of Pain Research. https://doi.org/10.2147/jpr.s393809
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.